Merck & Co.
JUPITER study: Cholesterol drug prevents coronary death even with normal cholesterol!
Submitted by Anonymous on Tue, 2008-11-11 10:05- Aging-associated diseases
- Astra-Zeneca
- AstraZeneca Plc
- Atorvastatin
- Biology
- Business
- Business
- Cardiology
- Cardiovascular diseases
- CHD
- Chief Executive Officer
- Cholesterol
- Columbia University
- Columbia University College of Physicians
- Coronary artery disease
- Crestor
- David Brennan
- Health
- Health
- Lipitor
- Lipoproteins
- Low-density lipoprotein
- Medicine
- Merck & Co.
- New England Journal
- New Orleans
- Person Career
- Pfizer Inc.
- Professor
- Rosuvastatin
- Statins
- the New England Journal of Medicine
- United States
- Zocor
A new study has found that cholesterol medicines known as "statins" may reduce the risk of strokes heart attacks and death by almost half when studied in patients with normal levels of cholesterol. With this finding at least 32 million people would be eligible for treatment. The drug studied is AstraZeneca Plc’s Crestor. The patients eligible for the study are those who have high amounts of a protein linked to inflammation.
»
- Read more
- 2838 reads